Publications by authors named "Philipp Fronik"

Claim this Profile
A
A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells.
Monika Caban, Philipp Fronik, Alessio Terenzi, Anja Federa, Julia H Bormio Nunes

Inorg Chem Front· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bitopic Ligands Support the Presence of a Metastable Binding Site at the β Adrenergic Receptor.
Birgit Isabel Gaiser, Mia Danielsen, Xinyu Xu, Kira Røpke Jørgensen, Philipp Fronik

J Med Chem· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance.
Philipp Fronik, Michael Gutmann, Petra Vician, Mirjana Stojanovic, Alexander Kastner

Commun Chem· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albumin-targeting of an oxaliplatin-releasing platinum(iv) prodrug results in pronounced anticancer activity due to endocytotic drug uptake .
Hemma Schueffl, Sarah Theiner, Gerrit Hermann, Josef Mayr, Philipp Fronik

Chem Sci· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands.
Philipp Fronik, Isabella Poetsch, Alexander Kastner, Theresa Mendrina, Sonja Hager

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry.
Philipp Fronik, Birgit I Gaiser, Daniel Sejer Pedersen

J Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis